Turnstone Biologics Corp.
TSBX
$0.35
$0.0319.72%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -37.38% | 2,139.75% | |||
| Gross Profit | 37.38% | -2,139.75% | |||
| SG&A Expenses | -18.41% | -8.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.30% | -16.72% | |||
| Operating Income | 33.30% | 16.72% | |||
| Income Before Tax | 32.56% | 16.21% | |||
| Income Tax Expenses | 202.33% | -40,900.00% | |||
| Earnings from Continuing Operations | 24.42% | 20.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.42% | 20.05% | |||
| EBIT | 33.30% | 16.72% | |||
| EBITDA | 33.36% | 17.08% | |||
| EPS Basic | 24.50% | 20.05% | |||
| Normalized Basic EPS | 27.74% | 16.21% | |||
| EPS Diluted | 24.50% | 20.05% | |||
| Normalized Diluted EPS | 27.74% | 16.21% | |||
| Average Basic Shares Outstanding | 0.10% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||